Promotion
Viewing
Entre-
preneurship
“
Transforming Hope into Reality: Pioneering Innovative Therapies for Triple-Negative Breast Cancer in China—Uniting Science, Compassion, and Vision to Create a Healthier Future for All.
Taking Off with Salmonella
Executive Summary
Overview of TNBC in China
Triple-negative breast cancer (TNBC) is a significant health challenge in China, accounting for 15-20% of all breast cancer cases, equating to approximately 63,000 to 84,000 new diagnoses annually. Characterized by its aggressive behavior and high recurrence rates (41.79%), TNBC lacks effective targeted therapies, as it does not express estrogen, progesterone, or HER2 receptors. The existing treatment landscape primarily relies on chemotherapy, which often fails to improve long-term outcomes, highlighting a substantial unmet need for innovative therapies that can enhance survival and quality of life for TNBC patients.
Market Analysis
The global cancer therapy market is rapidly expanding, projected to reach $250 billion by 2028, with a compound annual growth rate (CAGR) of 10-12%. In China, the oncology drug market is expected to reach $42 billion by 2028, driven by increasing demand for innovative treatments such as immunotherapies and monoclonal antibodies. For TNBC specifically, the potential market consists of 6,300 to 8,400 patients annually who could benefit from new treatments, with about 2,100 to 2,800 patients expected to afford the therapy. This represents a significant opportunity to capture a core market segment in a rapidly evolving oncology landscape, emphasizing the need for effective and accessible treatment options.
Profit Analysis
The T-SAT treatment is strategically priced at $10,000 per year, aligning with other innovative cancer therapies in China. Given that each patient requires treatment over a 5-year period, the total revenue generated per patient over the full treatment cycle amounts to $50,000. With an anticipated annual patient cohort of approximately 2,100 to 2,800, total revenue over five years could range from $105 million to $140 million. This pricing strategy balances market competitiveness with patient affordability while maintaining high-profit margins, positioning the company favorably in a lucrative oncology market.
Regulatory Environment and Approval Strategy
The National Medical Products Administration (NMPA) in China has established an encouraging regulatory framework for the approval of innovative cancer therapies, implementing fast-track approval processes. Our structured regulatory plan involves a timeline of 5-6 years, encompassing preclinical studies, Phase I-III clinical trials, and New Drug Application (NDA) submission. By leveraging priority review and conditional approval mechanisms, we aim to expedite market access, ensuring that our TNBC treatment can reach patients more quickly while gathering essential safety and efficacy data.
Financial Projections and Funding Strategy
To fund the $1 billion development and commercialization costs of the TNBC treatment, we plan to secure financing through a combination of venture capital and private equity ($400 million to $500 million), an initial public offering (IPO) ($400 million to $500 million), and government grants ($100 million to $150 million). With an expected annual revenue of $10,000 per patient and a total revenue potential of $625 million to $700 million over five years from a target cohort of 12,500 patients, our financial strategy positions the company for sustainable growth and profitability while addressing the critical needs of TNBC patients in China.
Table 1
Market Analysis for New TNBC Treatment Targeting China
1. TNBC Overview in China
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, which makes it unresponsive to hormonal and HER2-targeted therapies. In China, TNBC accounts for about 15-20% of all breast cancer cases. It is characterized by its aggressive nature, high recurrence rate (41.79%), and poor prognosis. The current treatment landscape largely relies on chemotherapy, as targeted therapies remain limited.
2. Unmet Need
TNBC remains a challenging type of cancer to treat due to its lack of receptors that are typically targeted in breast cancer therapies. Given the limited effectiveness of current treatment modalities and the aggressive nature of TNBC, there is a clear need for novel therapies that can improve survival outcomes. This unmet need represents a significant opportunity for innovation.
3. Market Size and Growth Potential
  • Breast Cancer Incidence: According to GLOBOCAN 2020, breast cancer is the most common cancer among Chinese women, with over 420,000 new cases annually. As TNBC accounts for 15-20% of these cases, this translates to approximately 63,000 to 84,000 new TNBC patients per year in China.
  • Growth Trends: The overall incidence of breast cancer in China has been rising due to factors like urbanization, changing lifestyles, and improved diagnostics. This trend is expected to continue, leading to a growing demand for new treatments.
  • Treatment Market: The Chinese market for cancer therapies, especially for targeted and immunotherapy, has been expanding rapidly, with significant investment in oncology R&D. According to recent estimates, the overall oncology drug market in China is projected to grow at a CAGR of 12.6% from 2021 to 2026.
4. Competitive Landscape
Currently, there are limited treatment options for TNBC beyond chemotherapy. The first-line treatment typically involves a combination of surgery, radiation, and chemotherapy, but the lack of specific targeted therapies creates an opportunity for novel treatments. Recent innovations in immunotherapy, PARP inhibitors, and antibody-drug conjugates are showing promise in clinical trials but have yet to become widely adopted.
5. Regulatory Environment
The Chinese regulatory environment has become more favorable for innovative cancer therapies. The National Medical Products Administration (NMPA) has accelerated the approval of novel oncology drugs under various fast-track schemes. Furthermore, China’s inclusion in the International Council for Harmonisation (ICH) has improved clinical trial standards, making it easier for companies to bring innovative therapies to market.
Table 1
Table 1
Cost Analysis
As shown in the chart, the costs are primarily divided into three parts: Proliferation Growth Costs, Packaging Costs, and Transportation Costs.
1. Proliferation Growth Costs:
  1. Growth Media Costs: Bacterial growth begins in LB or specialized media, costing $2 to $5 per liter. For a 10-liter batch, this results in a cost of $20 to $50 per batch.
  2. Incubation and Equipment Costs: Bioreactors or incubators maintain optimal growth. Operational costs range from $500 to $2,000 per batch, depending on batch size and monitoring requirements.
  3. Sterilization and Containment Costs: Sterilizing equipment and media incurs $200 to $400 per batch. Cleanroom environments add additional costs for sterile containment.
  4. Purification and Media Exchange: After growth, the bacteria are purified and transferred to an injectable buffer using techniques like centrifugation and filtration. This adds $500 to $2,000 per batch. Buffer costs range from $50 to $200 per liter, totaling $500 to $2,000 for a 10-liter batch.
  5. Quality Control and Testing: Regulatory testing ensures the product meets safety standards:
    • Sterility Testing: Costs $200 to $500 per batch.
    • Endotoxin Testing: Costs $100 to $300 per batch.
  6. Total Growth Cost Per Batch: Considering all steps, the total production cost per batch is $3,000 to $10,000, depending on scale and complexity.
  7. Cost per Dose: For a batch of 300 doses, the cost per dose ranges from $6.7 to $24.2, influenced by factors like purification efficiency, buffer choice, and quality control.
2. Packaging Costs
Packaging ensures both safety and regulatory compliance:
  • Sterile Packaging: Sterile vials or syringes cost between $1 to $5 per dose.
  • Labeling & Compliance: Regulatory labeling and packaging materials, including instructions and boxes, cost $2 to $5 per unit.
  • Regulatory Seals: Tamper-evident seals and additional safety packaging add $0.50 to $1 per dose.
  • Total Packaging Cost per Dose: $3.50 to $11.
3. Transportation Costs
Given the sensitive nature of biological treatments, cold chain logistics are necessary:
  • Cold Chain Logistics: Shipping refrigerated containers costs $20 to $50 per shipment within China, while local transportation typically ranges between $5 and $10 per shipment.
  • International Shipping: For global distribution, costs can rise to $50 to $100 per shipment.
  • Cost per Dose for Transportation: $1 to $10, depending on destination and shipment size.
Total Estimated Cost per Dose: By combining the costs of proliferation growth, packaging, and transportation, the total estimated cost per dose is between $11.23 and $45.17. This variation is influenced by production scale, packaging choices, and logistical considerations.
Table 1
Pricing Strategy for TNBC Treatment
To establish a competitive and sustainable pricing strategy for the new triple-negative breast cancer (TNBC) treatment, we have considered current oncology drug pricing trends in China and globally, including the cost of production, R&D investments, and market potential.
1. Market Overview
The Chinese oncology market is experiencing rapid growth, with projections indicating it will reach $42.19 billion by 2028. This growth is largely driven by the demand for innovative treatments such as monoclonal antibodies and small molecule therapies. These treatments are priced between $20,000 and $150,000 per year depending on the specific therapy and dosing frequency. For instance, Lapatinib, a drug used for treating HER2-positive breast cancer, can cost over $40,000 annually.
2. Cost and Pricing Analysis
Given the $1 billion R&D investment, it is crucial to align pricing with market expectations for similar biologic and targeted therapies:
  • Production Costs: Based on previous estimates, the production cost per dose ranges from $30 to $100, depending on the scale and logistics.
  • Market Price: In China, biologic cancer therapies are typically priced between $2,000 and $10,000 per dose, allowing for a balance between accessibility and profitability.
  • Clinical Value: The clinical efficacy of your treatment will justify a premium price, particularly if it can demonstrate improved survival or quality of life for TNBC patients.
3. Recommended Pricing
Based on comparisons with other innovative treatments, we recommend setting an initial price range of $10,000 to $50,000 annually. This allows for flexibility in pricing depending on dosage requirements and clinical outcomes. The higher end of this range would apply if the treatment proves highly effective in clinical trials or offers unique benefits compared to existing therapies.
4. Government Programs and Negotiation
In China, innovative therapies can leverage government programs such as NRDL price negotiations, which have successfully reduced the price of some cancer treatments by up to 60%. This strategy will make the treatment more accessible to a broader patient base while ensuring long-term market sustainability.
Pricing Strategy and Profit Estimation for New TNBC Treatment
Our new treatment for Triple-Negative Breast Cancer (TNBC) addresses a critical unmet need in the Chinese market. Below is a detailed pricing and profit forecast based on conservative market assumptions, estimated costs, and long-term scalability.
Target Market Assumptions
  • Total TNBC Patients: Every year, between 63,000 and 84,000 women in China are diagnosed with TNBC.
  • Treatment Sensitivity: Approximately 10% of TNBC patients (6,300 to 8,400 annually) are expected to respond positively to our new treatment based on clinical trial data.
  • Affordability: Due to income levels and insurance coverage, one-third of these patients, or around 2,100 to 2,800 patients annually, can afford the treatment.
Pricing Model
We have set a competitive treatment price of $10,000 per year, which is aligned with pricing for other innovative cancer treatments in China. This price balances accessibility for patients with maintaining high profitability for the company. The total cost per patient over the full 5-year treatment cycle is $50,000.
Cohort Model for 5-Year Treatment
Each year, we anticipate that 2,100 to 2,800 patients will start the treatment, and each patient will continue treatment for 5 years. After 5 years, we expect that up to 12,500 patients will have undergone treatment, distributed across the cohorts.
Cost of Production
The estimated production costs per dose vary based on several factors:
  • Proliferation Growth: Includes bacterial culture growth, purification, and quality control, with costs ranging from $6.7 to $24.2 per dose.
  • Packaging: Sterile packaging, labeling, and regulatory compliance cost between $3.50 to $11 per dose.
  • Transportation: Cold chain logistics and other transport costs vary from $1 to $10 per dose.
Revenue and Profit Estimation
Revenue Forecast
  • Annual Revenue per Patient: Each patient will generate $10,000 in revenue per year.
  • Total Revenue over 5 Years: For each patient completing the 5-year treatment cycle, total revenue will be $50,000.
  • Revenue from Total Cohort: For a cohort of 12,500 patients, the total revenue over 5 years will range between $625 million and $700 million, depending on cohort size.
Profit Forecast
With production costs per dose ranging from $11.23 to $45.17, the total production cost per patient over 5 years is expected to be $673.80 to $2,710.20.
  • Profit per Patient: Subtracting production costs from revenue, the profit per patient over 5 years will range from $47,290 to $49,326.
  • Total Profit from 12,500 Patients: Across the 5-year period, the total profit will range from $591 million to $616 million.
Profit Margins
The projected profit margins are substantial, with the profit margin ranging from 94.6% to 98.6%, based on the variation in production costs. This high profitability is driven by the low cost of production relative to the competitive pricing for premium oncology treatments.
Regulatory Approval Plan: NMPA Pathway for TNBC Treatment
To ensure the timely approval and market launch of our new triple-negative breast cancer (TNBC) therapy in China, a structured plan for approval through the National Medical Products Administration (NMPA) will be implemented. This plan leverages the latest regulatory frameworks and accelerates the process using priority review mechanisms for innovative oncology drugs.
1. Preclinical Development and IND Submission (Year 1)
  • Goal: Complete preclinical studies, including toxicology, pharmacokinetics, and proof of concept in animal models.
  • Timeline: 12-18 months.
  • Milestone: Submit an Investigational New Drug (IND) application to the NMPA, adhering to their electronic submission requirements, with the dossier formatted in eCTD (Electronic Common Technical Document) format.
  • Expected Outcome: Approval to commence human clinical trials within 3-6 months under the NMPA’s expedited oncology review process.
2. Phase I Clinical Trials (Year 2)
  • Objective: Assess the safety and dosage levels in 20–80 TNBC patients.
  • Duration: 12-18 months.
  • Strategy: Use an adaptive trial design to gather preliminary safety data quickly. Parallel discussions with NMPA will ensure readiness for Phase II progression upon successful results.
  • Regulatory Engagement: Maintain regular updates with the Center for Drug Evaluation (CDE) to ensure adherence to fast-track review pathways.
3. Phase II Clinical Trials (Year 3)
  • Objective: Investigate early efficacy in 100-300 patients.
  • Duration: 1-2 years.
  • Milestone: Submit interim analysis data to the NMPA for early efficacy signals and explore the possibility of conditional approval, as allowed for oncology drugs showing promising results.
  • Plan: Work closely with the CDE, leveraging the Priority Review and Conditional Approval mechanisms for innovative cancer treatments.
4. Phase III Clinical Trials (Year 4-5)
  • Objective: Confirm the efficacy and safety in a larger, randomized trial of 500-1,000 patients across multiple centers.
  • Timeline: 2-3 years.
  • Strategy: Based on Phase II results, apply for conditional approval after the second year, allowing the therapy to reach the market while Phase III data is still being collected. Post-marketing surveillance and additional efficacy data would be collected during this time.
5. New Drug Application (NDA) Submission (Year 5-6)
  • Objective: Submit a complete New Drug Application (NDA) for marketing approval.
  • Duration: 12 months.
  • Strategy: Ensure that the NDA includes all clinical data, manufacturing information, and long-term safety data. The submission will be completed using the NMPA’s electronic submission system, ensuring efficiency and compliance with the agency’s latest digital requirements.
  • Outcome: Full approval for commercialization in China within 6 years, with the potential for market access by Year 5 if conditional approval is granted earlier.
6. Post-Marketing Surveillance and Data Collection (Year 6+)
  • Objective: Collect additional safety and efficacy data through a post-marketing surveillance study.
  • Plan: Submit follow-up data to the NMPA to confirm the long-term benefits of the treatment, meeting the conditional approval requirements and ensuring continued market presence.
Regulatory Support and Fast-Track Options
  • Priority Review: As an innovative treatment for TNBC, which addresses a significant unmet need, this drug will be eligible for priority review, cutting approval timelines by up to 50%.
  • Conditional Approval: Based on strong early clinical data, we will apply for conditional approval, allowing the drug to enter the market before Phase III trials are fully completed.
  • eCTD Submission: All submissions will be prepared in the NMPA's eCTD format to ensure fast processing and compliance with their latest digital submission requirements.
This regulatory plan ensures that our TNBC treatment will achieve NMPA approval within 5-6 years, leveraging fast-track approval processes. Early market entry via conditional approval will maximize the financial return on investment while providing life-saving treatment to thousands of TNBC patients across China.
Table 1
Financing Plan for $1 Billion Cost
To fund the development and commercialization of the new TNBC treatment, the most practical approach involves securing a combination of Venture Capital and Private Equity, an Initial Public Offering (IPO), and Government Grants. This strategy ensures that each stage of development is fully supported while minimizing risks.
1. Venture Capital & Private Equity ($400 million to $500 million)
The initial financing will come from venture capital and private equity to raise $400 million to $500 million. This capital will be directed toward R&D, preclinical work, and early-stage clinical trials (Phase I and II). Notably, oncology remains a top focus for Chinese investors, and the biotech market has rebounded since the pandemic. In recent years, biotech IPOs have shown strong interest from investors, especially in oncology and innovative drug development sectors.
2. Initial Public Offering (IPO, $400 million to $500 million)
Upon completing Phase II clinical trials, the company will pursue an IPO on the Hong Kong Stock Exchange (HKEX) or the Shanghai STAR Market, which have become prime destinations for pre-revenue biotech firms. The IPO is expected to raise $400 million to $500 million, which will be used to fund Phase III clinical trials, production scaling, and preparation for market entry.
3. Government Grants and Subsidies ($100 million to $150 million)
In parallel with private funding, the company will secure government grants and subsidies to raise $100 million to $150 million. China's government actively supports innovative drug development through programs such as the National High-tech R&D Program (863 Program). These funds are non-dilutive and will help offset clinical trial costs and initial manufacturing expenses.
Table 1
References
  1. Chinese Anti-Cancer Association Breast Cancer Professional Committee, Chinese Anti-Cancer Association International Medical Exchange Branch, Breast Cancer Study Group of the Chinese Medical Doctor Association Tumor Physician Branch. (2024). Clinical guidelines for the diagnosis and treatment of advanced triple-negative breast cancer in China (2024 edition) [J]. Chinese Journal of Oncology, 46(6), 471-480. https://doi.org/10.3760/cma.j.cn112152-20240118-00034.
  2. Zhao, H., Feng, Y., & Yang, J. (2021). The clinical feature of triple-negative breast cancer in Beijing, China. medRxiv.
  3. Zhou, J., Lan, T., Lu, H., & Pan, J. (2024). Price negotiation and pricing of anticancer drugs in China: An observational study. PLOS Medicine, 21(1), e1004332.
  4. IQVIA Institute for Human Data Science. (2024). Global Oncology Trends 2024: Outlook to 2028. Published May 28, 2024. IQVIA.
  5. Bao, Y., Liu, Y., Ma, R., Zhang, P., & Li, X. (2023). The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China. Journal of Global Health.
  6. Toso, John F., et al. "Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma." Journal of Clinical Oncology, vol. 20, no. 1, 2002, pp. 142-152. https://doi.org/10.1200/jco.20.1.142.
  7. Centers for Disease Control and Prevention. "Vaccine Storage and Handling Toolkit." 2023. Available at: https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf.
  8. Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2024). Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 4(1), 47-53.
  9. BioWorld, 2024. Chapter 18A Entices Biotechs to List on Hong Kong Exchange. BioWorld, September 2024.
  10. Skadden, Arps, Slate, Meagher & Flom LLP, 2024. 2024 Report on Hong Kong-Listed Biotech Companies. June 2024.
  11. S&P Global Market Intelligence, 2024. Hong Kong Biotech IPO Outlook Positive Amid Heightened Market Volatility. S&P Global, June 2024.